Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections?
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
pubmed:
20
1
2019
medline:
30
6
2019
entrez:
20
1
2019
Statut:
ppublish
Résumé
Sleeve lobectomy represents a safe and effective treatment for central NSCLC to avoid the risks of pneumonectomy. Induction therapy (IT) may be indicated in advanced stages; however, the effect of IT on bronchial anastomoses remains uncertain. The purpose of the study was to evaluate the impact of IT on the complications of the anastomoses. Between 2000 and 2012, 159 consecutive patients were submitted to sleeve lobectomy for NSCLC at our Institution. We retrospectively compared the results of patients who underwent IT before operation with those who received upfront surgery. In the study period, 49 (30.8%) patients received IT (37 chemotherapy, 1 radiotherapy and 11 chemo-radiotherapy) and 110 (69.2%) patients were directly submitted to surgery (S). The two groups were comparable for sex, age, comorbidities, ASA score, pulmonary function, side, type of procedure and histology. Pathological stage was statistically higher for IT group (p = 0.001). No differences between IT and S groups were observed in terms of post-operative mortality (2% vs 0%, p = NS), morbidity (45% vs 38%, p = NS), including early (6% vs 9%, p = NS) and long-term (16% vs 14%, p = NS) bronchial complication rates. Patients undergoing induction mediastinal radiotherapy, however, are at higher risk of bronchial complications. In our experience, the use of induction chemotherapy did not significantly increase mortality and morbidity rates, in particular, neither for early nor for late anastomotic complications. We, therefore, conclude that sleeve lobectomy after induction chemotherapy is safe and reliable procedure for the treatment of locally advanced NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Sleeve lobectomy represents a safe and effective treatment for central NSCLC to avoid the risks of pneumonectomy. Induction therapy (IT) may be indicated in advanced stages; however, the effect of IT on bronchial anastomoses remains uncertain. The purpose of the study was to evaluate the impact of IT on the complications of the anastomoses.
METHODS
METHODS
Between 2000 and 2012, 159 consecutive patients were submitted to sleeve lobectomy for NSCLC at our Institution. We retrospectively compared the results of patients who underwent IT before operation with those who received upfront surgery.
RESULTS
RESULTS
In the study period, 49 (30.8%) patients received IT (37 chemotherapy, 1 radiotherapy and 11 chemo-radiotherapy) and 110 (69.2%) patients were directly submitted to surgery (S). The two groups were comparable for sex, age, comorbidities, ASA score, pulmonary function, side, type of procedure and histology. Pathological stage was statistically higher for IT group (p = 0.001). No differences between IT and S groups were observed in terms of post-operative mortality (2% vs 0%, p = NS), morbidity (45% vs 38%, p = NS), including early (6% vs 9%, p = NS) and long-term (16% vs 14%, p = NS) bronchial complication rates. Patients undergoing induction mediastinal radiotherapy, however, are at higher risk of bronchial complications.
CONCLUSION
CONCLUSIONS
In our experience, the use of induction chemotherapy did not significantly increase mortality and morbidity rates, in particular, neither for early nor for late anastomotic complications. We, therefore, conclude that sleeve lobectomy after induction chemotherapy is safe and reliable procedure for the treatment of locally advanced NSCLC.
Identifiants
pubmed: 30659342
doi: 10.1007/s00268-019-04908-0
pii: 10.1007/s00268-019-04908-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1385-1392Références
J Thorac Cardiovasc Surg. 2000 Apr;119(4 Pt 1):814-9
pubmed: 10733774
J Thorac Cardiovasc Surg. 2000 May;119(5):939-45
pubmed: 10788815
Lung Cancer. 2002 Apr;36(1):91-7
pubmed: 11891039
Ann Thorac Surg. 2002 Sep;74(3):851-8; discussion 858-9
pubmed: 12238850
J Thorac Cardiovasc Surg. 1992 Oct;104(4):888-91
pubmed: 1405686
Ann Thorac Surg. 2003 Dec;76(6):1782-8
pubmed: 14667584
Radiother Oncol. 2004 May;71(2):139-46
pubmed: 15110446
Ann Thorac Surg. 2005 Aug;80(2):418-21; discussion 422
pubmed: 16039176
Ann Thorac Surg. 1992 Aug;54(2):387-91
pubmed: 1637243
Eur J Cardiothorac Surg. 2007 Jul;32(1):20-8
pubmed: 17442581
Eur J Cardiothorac Surg. 2008 Sep;34(3):488-92; discussion 492
pubmed: 18579399
Ann Thorac Surg. 2009 Mar;87(3):975-6
pubmed: 19231447
J Thorac Oncol. 2009 Sep;4(9):1049-59
pubmed: 19652623
Ann Thorac Surg. 2009 Sep;88(3):945-50; discussion 950-1
pubmed: 19699925
Ann Thorac Surg. 2009 Dec;88(6):1732-5
pubmed: 19932225
Interact Cardiovasc Thorac Surg. 2010 Oct;11(4):425-8
pubmed: 20656802
Eur J Cardiothorac Surg. 2012 May;41(5):1052-8
pubmed: 22223693
Eur J Cardiothorac Surg. 2012 Jul;42(1):77-81
pubmed: 22290903
J Natl Compr Canc Netw. 2012 May;10(5):599-613
pubmed: 22570291
Ann Thorac Surg. 2013 Jul;96(1):247-52
pubmed: 23684158
Thorac Surg Clin. 2013 Aug;23(3):273-85
pubmed: 23931012
J Thorac Cardiovasc Surg. 1997 Nov;114(5):830-5; discussion 835-7
pubmed: 9375614